{"id":605858,"date":"2026-09-04T17:22:08","date_gmt":"2026-09-04T17:22:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/605858\/"},"modified":"2026-09-04T17:22:08","modified_gmt":"2026-09-04T17:22:08","slug":"new-ms-cell-therapy-builds-immune-tolerance-to-protect-myelin","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/605858\/","title":{"rendered":"New MS cell therapy builds immune tolerance to protect myelin"},"content":{"rendered":"<p>A new experimental cell therapy that pairs a patient\u2019s own red blood cells with myelin protein fragments safely calmed the immune system and helped dampen the inflammatory attack that drives <a href=\"https:\/\/multiplesclerosisnewstoday.com\/multiple-sclerosis-overview\/\" rel=\"nofollow noopener\" target=\"_blank\">multiple sclerosis<\/a> (MS), according to results from an early-stage clinical trial.<\/p>\n<p>The novel approach works by retraining the body\u2019s immune system to recognize <a href=\"https:\/\/multiplesclerosisnewstoday.com\/myelin-sheath\/\" rel=\"nofollow noopener\" target=\"_blank\">myelin<\/a> as friendly rather than a target. By promoting immune tolerance specifically to myelin, the treatment aims to control disease activity without causing broad immune suppression.<\/p>\n<p>Trial results showed that the cell therapy was well tolerated, increased key immune-regulating cells, and reduced a blood marker associated with nerve damage.<\/p>\n<p>The work was led by scientists at the University of Zurich (UZH) in Switzerland. Several of the researchers have co-founded a company called <a href=\"https:\/\/www.cellerys.com\/\" rel=\"nofollow noopener\" target=\"_blank\">Cellerys<\/a> to further develop this approach.<\/p>\n<p>  Recommended Reading<\/p>\n<p>        <img decoding=\"async\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/09\/iStock-1141006114-150x0-c-default.jpg\" alt=\"A photo shows white matter in the brain.\"\/><\/p>\n<p>Restoring immune tolerance in MS<\/p>\n<p>\u201cThis would make it possible to suppress this autoimmune disease in a very targeted manner and without major side effects,\u201d Andreas Lutterotti, MD, the study\u2019s corresponding author and a co-founder of Cellerys, said in a <a href=\"https:\/\/www.news.uzh.ch\/en\/articles\/media\/2026\/multiple-sclerosis-autoimmune-response.html\" rel=\"nofollow noopener\" target=\"_blank\">news story from UZH<\/a>. \u201cThis approach can also be applied to many of the more than one hundred autoimmune diseases.\u201d<\/p>\n<p>The study, \u201c<a href=\"https:\/\/www.pnas.org\/doi\/abs\/10.1073\/pnas.2614908123\" rel=\"nofollow noopener\" target=\"_blank\">Treatment of multiple sclerosis with peptide-coupled red blood cells induces antigen-specific T regulatory cells<\/a>,\u201d was published in PNAS.<\/p>\n<p>In the immune system, which protects the body from infections, anything recognized as a normal part of the body is left alone, while things that are not may be seen as potential threats and attacked. The immune system\u2019s ability to recognize and avoid attacking the body\u2019s own tissues is known as immune tolerance.<\/p>\n<p>Autoimmune diseases are characterized by a breakdown of immune tolerance, leading the immune system to mistakenly attack healthy parts of the body. MS is specifically driven by an immune attack that targets myelin, a fatty substance that normally protects nerve cells and helps them send electrical signals.<\/p>\n<p>Retraining the immune system to recognize myelin as safe could theoretically restore immune tolerance and stop disease progression.<\/p>\n<p>In this study, researchers tested an approach to do this using red blood cells, which are responsible for carrying oxygen through the bloodstream.<\/p>\n<p>How the treatment works<\/p>\n<p>Red blood cells have a short lifespan and are continuously replaced by the body. At the same time, there are biological systems in place to dispose of the pieces of broken-down red blood cells. These systems also play a role in regulating the immune system and maintaining immune tolerance, helping prevent the body from mounting an inappropriate immune response against its own red blood cells.<\/p>\n<p>This new approach takes advantage of these features. Essentially, the treatment works by collecting a patient\u2019s red blood cells, then attaching small pieces of myelin that are known to be targeted by the immune system in MS. The myelin-coupled red blood cells are then transfused back into the patient. As blood cells break down naturally, myelin fragments are swept up by the same disposal system that helps regulate immune tolerance. This presents myelin to the immune system in a way that promotes tolerance, essentially teaching the immune system to stop attacking it.<\/p>\n<p>Cellerys sponsored a <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06430671\" rel=\"nofollow noopener\" target=\"_blank\">Phase 1b clinical trial (NCT06430671)<\/a> that assessed the safety of this treatment strategy in 10 people with MS. The results indicated that the therapy was generally safe and well tolerated.<\/p>\n<p>At the same time, immunological data indicated that the treatment increased the levels of regulatory T-cells, which are immune cells that play a key role in maintaining immune tolerance.<\/p>\n<p>Clinical and imaging readouts remained generally stable throughout the study. Researchers observed a reduction in the levels of neurofilament light chain, a marker of nerve damage, \u201cindicating reduced tissue inflammation in the brain.\u201d<\/p>\n<p>Overall, the researchers concluded that this approach is a \u201cpromising autologous cell therapy for achieving antigen-specific immune tolerance in MS.\u201d Cellerys is further developing this treatment approach under the name CLS12311.<\/p>\n","protected":false},"excerpt":{"rendered":"A new experimental cell therapy that pairs a patient\u2019s own red blood cells with myelin protein fragments safely&hellip;\n","protected":false},"author":2,"featured_media":605859,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-605858","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/605858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=605858"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/605858\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/605859"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=605858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=605858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=605858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}